compounded semaglutide being discontinued Hims & Hers stock falls 25% as FDA curtails GLP-1s Hims and Ro Stopped Selling

However, CMS is delaying the beginning of that program to give insurance companies more time to study the effects of coverage of GLP-1 on utilization and costs

The right comparison depends on what problem needs solving: side effects, kidney dosing, convenience, interaction with other drugs, or a broader treatment goal

Tirzepatide also demonstrated improvements in cardiometabolic measures

Ozempic slows down the gastric emptying, sometimes leading to sulfur build-up in cases of certain dietary choices

E.NowakR

The physiological relevance of an electrochemical parameter measured under such artificial conditions may be questioned